Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by $1.38, provides guidance Feb 26, 2026 06:06AM
Leerink Partners Downgrades Aurinia Pharmaceuticals (AUPH) to Market Perform Dec 3, 2025 06:40AM
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) to Buy Nov 7, 2025 02:50AM
RBC Capital Downgrades Aurinia Pharmaceuticals (AUPH) to Sector Perform Nov 4, 2025 04:43PM
Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 7c ; Offers Guidance Nov 4, 2025 06:01AM


Oct 15, 2025 06:01AM Aurinia to present LUPKYNIS data at medical conferences
Sep 30, 2025 05:01AM Aurinia defends LUPKYNIS after FDA official retracts LinkedIn post
Sep 30, 2025 02:37AM Jefferies Reiterates Hold Rating on Aurinia Pharmaceuticals (AUPH)
Aug 4, 2025 05:28AM Aurinia Pharmaceuticals (AUPH) call put ratio 62 calls to 1 put with a focus on August and September calls
Jul 31, 2025 06:03AM Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 2c ; Offers Guidance
Jul 30, 2025 06:34AM H.C. Wainwright Assumes Aurinia Pharmaceuticals (AUPH) at Buy
Jun 30, 2025 01:10PM Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
Jun 30, 2025 01:09PM TD Cowen Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
Jun 30, 2025 06:01AM Aurinia Pharmaceuticals (AUPH) Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
May 12, 2025 08:21AM Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
May 12, 2025 06:08AM Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 5c, provides guidance
Feb 27, 2025 06:01AM Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c, provides guidance
Nov 11, 2024 06:20AM Aurinia Pharmaceuticals (AUPH) PT Raised to $9 at RBC Capital
Nov 7, 2024 02:04PM Aurinia Pharmaceuticals (AUPH) 2600 contracts of January 12 calls trade as share price up 13%
Nov 7, 2024 09:08AM Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c
Nov 7, 2024 06:10AM Aurinia Pharmaceuticals (AUPH) Announces Board Changes
Nov 7, 2024 06:02AM Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c ; Offers Guidance
Oct 11, 2024 06:01AM Aurinia Pharmaceuticals (AUPH) Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS in Treating Lupus Nephritis
Sep 24, 2024 08:10AM Aurinia Pharmaceuticals (AUPH) Japan Approval of LUPKYNIS to Treat Lupus Nephritis
Sep 12, 2024 04:05PM Aurinia Pharmaceuticals (AUPH) Announces Board Restructuring
Sep 6, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
Sep 5, 2024 07:22AM Aurinia Pharmaceuticals (AUPH) Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Aug 13, 2024 08:00AM Aurinia Pharmaceuticals (AUPH) Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board
Aug 1, 2024 06:04AM Aurinia Pharmaceuticals (AUPH) Reports In-Line Q2 EPS, narrows guidance